Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era.

Ting Martin Ma, Felix Y Feng, Seth A Rosenthal, Matthew B Rettig, Ann C Raldow, Daniel E Spratt, Michael Xiang, Amar U Kishan

Abstract read

PubMed Publisher

In one paragraph

Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ting Martin MaDepartment of Radiation Oncology, University of California, Los Angeles, CA, USA.ORCID 0000-0002-0053-7874

Felix Y FengDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0963-7687

Seth A RosenthalDepartment of Radiation Oncology, Sutter Medical Group, Roseville, CA, USA.

Matthew B RettigDepartment of Urology, University of California, Los Angeles, CA, USA.

Ann C RaldowDepartment of Radiation Oncology, University of California, Los Angeles, CA, USA.

Daniel E SprattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0002-5973-4741

Michael Xiang *Department of Radiation Oncology, University of California, Los Angeles, CA, USA.ORCID 0000-0003-0170-9321

Amar U Kishan *Department of Radiation Oncology, University of California, Los Angeles, CA, USA. Aukishan@mednet.ucla.edu.ORCID 0000-0002-7437-6591

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is unclear whether cancer patients enrolled in clinical trials have improved outcomes compared with non-study patients. We compared prostate cancer-specific mortality (PCSM) in patients in a real-world setting (SEER-Medicare database) versus on a trial (NRG/RTOG 0521). The 7-year freedom from PCSM was superior in trial patients (92.4% vs. 88.1%, sHR = 1.77 [95% CI 1.05-2.97], P = 0.03). Black trial patients had significantly superior freedom from PCSM than Black real-world patients (sHR 6.52, 95% CI 1.43-29.72, P = 0.02), which was not seen among non-Black patients. Trial patients may have improved outcomes, and racial disparities are accentuated in the real world.

Indexed as

Prostatic NeoplasmsAgedHumansMaleMedicareProstateProstate-Specific AntigenSEER ProgramUnited StatesProstate-Specific Antigen

Identifiers

PMID36966268

DOI10.1038/s41391-023-00663-5

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.